ITV plc (ITV) noted the recent press speculation and confirms that it is in preliminary discussions regarding a possible sale of its M&E business to Sky for an enterprise value of £1.6bn. There can be no certainty as to the terms upon which any potential sale may be agreed or whether any transaction will take place. A further announcement will be made in due course if appropriate.
Comment: One of the longstanding dogs amongst blue chip stocks. It may be the case that even if the £1.6bn sale goes ahead, the share price of ITV will still not fail to disappoint.
Rightmove plc (RMV) shares slumped more than 15% in early London trading after the UK’s largest online property portal announced plans to step up investment in artificial intelligence (AI) and rebuild its digital infrastructure — moves that investors fear could weigh on near-term profits.
In its latest trading update, Rightmove forecast underlying operating profit growth of just 3–5% in 2026, down from 4–9% expected across 2024 and 2025. The slowdown disappointed markets, even as the company said it continues to generate “strong business value” from its platform.
Tungsten West (TUN), the mining company focused on restarting production at the Hemerdon tungsten and tin mine in Devon, UK, is pleased to report positive progress from the ongoing processing trial at Hemerdon. The trial is being undertaken as part of a programme focused on testing and optimising the performance of key sections of the mineral processing facility. The programme forms part of the Company’s approach to de-risking operations and gathering technical data essential for the planned restart of full-scale production.
Comment: Tungsten may now be a shiny critical metals, something which has propelled TUN well over the course of this year in share price terms. That said, we are reminded to day of the nitty gritty of getting into production.
The Small-Cap Rebuild: Six UK-Listed Companies Turning Strategy into Execution
Trellus Health® plc (TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announced it has signed a 12 month contract (the “Contract”) with one of the largest global clinical research organisations (‘CRO’s’) to utilise its Trellus TrialSet™ offering. The Contract is due to commence before year end, and will focus on immunology and inflammation, supporting recruitment and enrolment optimisation for two late-stage clinical trials. This marks the Company’s second contract with a leading CRO.
Comment: TRLS looks like it has achieved a significant inflection point as far as its business is concerned, and one would expect further momentum in the contract wins. Still the shares are well down on where they were earlier in the year, something which suggests the market wants to see further proof of the validity and value in its business model.
MedPal AI (MPAL), a UK-based digital health and artificial intelligence (“AI”) company focused on wellness management, announced the launch of MedPal.clinic, its retail pharmacy website. The Directors believe that MedPal.clinic represents a UK-first in digital pharmacy services, combining AI-powered triage with access to qualified Independent Prescribers (“IPs”) and General Practitioners (“GPs”), delivered through a multimodal communications platform. Users can access clinical consultations via their preferred communication method, including text messaging and WhatsApp, providing unprecedented flexibility and convenience in accessing primary care services.
Comment: MPAL is in a hot space, and there has been significant roll out newsflow since the company came to market a couple of months ago. One would expect this momentum to slowly be reflected in the share price.
Blencowe Resources Plc (BRES) provides a summary of key points discussed by Chief Executive Officer Mike Ralston in a recorded interview. The interview focuses on the Company’s strategy to de‑risk and advance the Orom‑Cross Graphite Project in Uganda, progress towards a JORC Resource & Reserve update, and complete the Definitive Feasibility Study (“DFS”) including in‑country downstream purification. In the interview, Mr. Ralston explains how Blencowe’s de-risking strategy has successfully positioned Orom-Cross as one of the most advanced graphite development projects globally, supported by US and EU initiatives, and underpinned by having all of the six key fundamentals considered critical for success in mining graphite projects.
Comment: It feels like we have almost daily content out from BRES, and no one can say that Ralston is not keen to get the message out. This is perhaps understandable given the way that the shares still trade near 6p, below 2021 highs, when so much has been achieved by the company since then.
Falconedge plc (AQSE: EDGE), provider of turnkey advisory solutions for asset and fund managers with currently 5 retained clients, is pleased to announce that it has bought 15.162582280 Bitcoin as part of its treasury management for its underlying advisory business. The Company will utilise its Bitcoin to earn low risk compounding yield through diversified financial mechanisms. Number of Bitcoin Purchased: 15.162582280 Bitcoin. Average Purchase Price: £ 79,109.22 per Bitcoin (Approx. $103,553.97 per Bitcoin). Amount Purchased: £1,199,500.00.
Comment: New to the market this week, and getting its BTC at a rather lower price than many of late, we have EDGE hitting the ground running in terms of its strategy. The interest here is how much the company can deliver in terms of its promise of compounding yield.
CAP-XX Limited (CPX), a world leader in the design and manufacture of thin, prismatic supercapacitors and energy management systems, is pleased to announce its audited results for the year ended 30 June 2025 and provide an update on current trading. Audited results for the year ended 30 June 2025. Total revenue of A$4.94m (FY24: A$4.59m) has increased by 7.6%. Gross margin of 29.7% broadly in line with last year (FY24: 30.0%). EBITDA loss of A$3.04m (FY24: A$5.11m) a 40.5% improvement. Loss after tax of A$3.93m (FY24: A$6.14m*) a 36.0% improvement. Cash as at 30 June 2025 was A$3.96m.
Comment: Despite today’s initial share price fall, shares of CPX are still up 74% YTD, as the market looks to the company as being a recovery situation. While there is still work to do to erase the latest loss, an improvement on last time, we see enough here to assume that the shares will revisit year highs through 0.45p early in 2026.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
